- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.04. | Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026 | ||
| 02.04. | Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression | ||
| 02.04. | Glenmark goes direct with new US Ryaltris marketing plan as it drops partner model | ||
| 02.04. | German CDMO Adragos buys French sterile injectables plant from Sanofi | ||
| 02.04. | Bayer rejigs marketing claims after recommendation from US advertising body | ||
| 02.04. | Regulatory tracker: Vertex secures broader FDA labels for cystic fibrosis meds Alyftrek, Trikafta | ||
| 01.04. | Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo | ||
| 01.04. | Novo's Wegovy nets cardio nod from UK cost gatekeeper, adding 1M+ eligible patients | ||
| 01.04. | Evotec hires exec with AI experience to lead rebooted commercial team | ||
| 31.03. | FDA flags serious liver injury cases, 8 deaths with 'reasonable' link to Amgen's Tavneos | ||
| 31.03. | Novo Nordisk cuts 400 roles at troubled Bloomington site | ||
| 31.03. | Iterum initiates wind-down after failure to offload antibiotic with sluggish sales | ||
| 31.03. | API supplier BASF raises prices up to 20% in response to rising energy, raw material costs | ||
| 31.03. | Biogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds | ||
| 31.03. | Insulet hires Stryker vet, reinstating commercial chief role as C-suite overhaul continues | ||
| 30.03. | Lilly presses for UK deal that would see higher drug prices in exchange for resumed investments: FT | ||
| 30.03. | United plots Tyvaso FDA filing after ph. 3 win elicits talk of 'new IPF standard' and blockbuster sales | ||
| 30.03. | BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters | ||
| 30.03. | Idorsia eyes pediatric insomnia use with midstage trial win for sleep med Quviviq | ||
| 30.03. | Takeda begins US layoffs as part of massive $1.3B restructuring | ||
| 30.03. | Samsung Biologics union gathers votes to strike as tension over wage, governance mounts | ||
| 30.03. | Biogen looks to shake up SMA status quo with FDA nod for high-dose version of Spinraza | ||
| 27.03. | 'Health Doesn't Need to Be Ludacris': Bayer signs rapper-actor to multivitamin campaign | ||
| 27.03. | Rocket charts measured trajectory for new gene therapy Kresladi after clearance to launch from FDA | ||
| 27.03. | Fierce Pharma Asia-Takeda's $1.3B reorg; India's GLP-1 floodgates; Gilead's $2.2B buy of a China NewCo |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.